<DOC>
	<DOCNO>NCT02181946</DOCNO>
	<brief_summary>The purpose study determine effect nevirapine steady state pharmacokinetics fluconazole assess steady-state pharmacokinetics nevirapine give combination fluconazole .</brief_summary>
	<brief_title>Effects Nevirapine Steady State Pharmacokinetics Fluconazole HIV Positive Patients</brief_title>
	<detailed_description />
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Nevirapine</mesh_term>
	<mesh_term>Fluconazole</mesh_term>
	<criteria>Male female patient age 18 65 year seropositive HIV1 antibody ELISA test confirm alternative method , e.g . Western Blot CD4 + cell count â‰¥ 100 cells/mm3 Patients meet follow laboratory parameter Granulocyte count &gt; 1000 cells/mm3 Hemoglobin &gt; 9.0 g/dl ( men woman ) Platelet count &gt; 75,000 cells/mm3 Alkaline phosphatase &lt; 3.0 time upper limit normal Aspartame Transaminase ( AST ) Alanine Transaminase ( ALT ) &lt; 3.0 time upper limit normal Total bilirubin &lt; 1.5 time upper limit normal Female patient childbearing potential must willing use reliable form contraception must include medically approve barrier contraception Patients able provide write informed consent comply study requirement Female patient pregnant breastfeeding Seated systolic blood pressure 100 mmHg , great 160 mmHg , and/or heart rate le 50 great 100 beats/min History drug allergy know drug hypersensitivity Patients receive investigational drug , antineoplastic agent radiotherapy local skin radiotherapy treatment within 12 week start study medication Patients require systemic treatment corticosteroid drug know hepatic enzyme inducer inhibitor within 28 day study entry ( Study Day 1 ) . Such substance category include : macrolide antibiotic ( e.g . erythromycin , clarithromycin , azithromycin , dirithromycin ) , azole antifungal ( e.g . itraconazole ) , rifabutin phenytoin Patients require systemic treatment CYP3A4 ( cytochrome P450 3A4 ) substrate terfenadine , astemizole , cisapride , triazolam midazolam course trial Use protease inhibitor nonnucleoside reverse transcriptase inhibitor within 28 day Study Day 1 trial Patients current history intravenous drug abuse , alcohol substance abuse ( within last year ) History clinically important disease include hepatic , renal , cardiovascular gastrointestinal disease Patients malabsorption , severe chronic diarrhea patient unable maintain adequate oral intake</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>